RxDoctor Payments Data

Carlo Sebello, NP

Primary Care · Jersey City, NJNPI 1801556857

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 349 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 15.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $3,318 and has fallen 88.4% since, to $384 in 2025. Among primary care clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$7,949in general payments, 2019–2025

Across 349 payments — averaging $22.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • Lilly USA, LLC$849
  • GSK$802
  • Novo Nordisk$795
  • AstraZeneca$778
  • Johnson & Johnson$757
  • plus $3K from 28 others

What the payments were for

  • Food & beverage$7,949100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,949 in reported general payments places this provider in the 95th percentile of 330 primary care providers in New Jersey.

See all primary care providers in New Jersey

Medicare billing

Part B allowed, 2024
$26,180
Medicare patients
96
Services billed
272

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol136$182,879
OzempicSemaglutide80$163,038
OtezlaApremilast11$147,357
JanuviaSitagliptin Phosphate110$145,105
JardianceEmpagliflozin108$138,151
RybelsusSemaglutide52$121,555
Xigduo XrDapaglifloz Propaned/Metformin94$112,076
Synjardy XrEmpagliflozin/Metformin Hcl91$111,314
TrulicityDulaglutide44$90,714
LinzessLinaclotide54$55,472
MounjaroTirzepatide31$50,425
Trelegy ElliptaFluticasone/Umeclidin/Vilanter54$43,521
VascepaIcosapent Ethyl84$42,885
EliquisApixaban26$38,392
Bydureon BciseExenatide Microspheres22$29,501

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$795$284,593132 claims
Boehringer IngelheimJardiance, Synjardy Xr, Synjardy$751$278,918228 claims
AstraZenecaFarxiga, Breztri Aerosphere$778$212,087163 claims
AmgenOtezla, Prolia$1,200$169,44024 claims
MerckJanuvia, Segluromet$58$155,279126 claims
Lilly USA, LLCTrulicity, Mounjaro$849$141,13975 claims
AbbVieLinzess$127$55,47254 claims
GSKTrelegy Ellipta, Shingrix$802$46,69771 claims
PfizerEliquis$17$38,39226 claims
Johnson & JohnsonXarelto$757$18,45218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 330 primary care providers in New Jersey.

Other primary care in Jersey City

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →